July 16, 2026 |
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize opportunities, and optimize commercial strategy.
InConcert™ brings together omnichannel, field, clinical, and predictive insights in a single decision-making environment – helping commercial teams make smarter, faster decisions backed by Intelligent Commercialization™.

If you’re looking for a quick, easy-to-understand overview of InConcert™, this one-page guide is the perfect place to start.
In just a few minutes, you’ll discover:
Whether you’re exploring InConcert™ for the first time or introducing it to key stakeholders, this concise overview explains everything you need to know – all on a single page.
Download now.
This content was provided by Inizio
Latest Content from Inizio
The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014.With turnover…
Using our combined knowledge and years of experience of working in these territories, our experts have produced an essential guide to help address some of the core challenges for conducting market…
This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that…
Published in Medical Marketing & Media November 2015
Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets
Published in eyeforpharma 16 November by Rachel Howard
Our latest case study demonstrates how a mobile app methodology was used to deliver key insights into issues faced by COPD patients
Published in pharmaphorum October 2015 by Laurent Chanroux
Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and consider the possible implications for market researchers.
Published in eyeforpharma 12 October by Rachel Howard
